eureKARE believes that synthetic biology, microbiome research, and the intersection between them can help tackle critical challenges and create a healthier, more prosperous, and sustainable world. They see Europe's strength in fundamental sciences as dramatically under-exploited and aim to harness the strengths of Europe's knowledge economy by investing in its brightest minds. They aim to support scientists' commercialization efforts, creating new jobs, companies, and novel industries along with the disruptive technology they bring to market. They focus on applications in healthcare, ranging from new cell therapies and microbiome-based medicines to life-saving gene therapies, and also environmental applications, such as creating better biofuels, restoring species diversity, and fighting pollution. The firm aims to fill the funding and support gap for entrepreneurship in the synthetic biology field, where Europe excels in research but lags in commercialization. They envision a world where synthetic biology plays a transformative role in solving some of the world's most pressing challenges, revolutionizing industries, creating new markets, and providing solutions to complex problems. eureKARE is committed to supporting the development and growth of synthetic biology companies, and their portfolio reflects their commitment to advancing the field and creating a more sustainable and equitable world.
Preferred startup development maturity for initial funding deployment.
Synthetic biology, microbiome research, healthcare, agriculture, energy, environmental sustainability
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...